echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Int J Clin Oncol: The efficacy of commercial CAR T cells in the treatment of relapsed/refractory aggressive B-cell lymphoma

    Int J Clin Oncol: The efficacy of commercial CAR T cells in the treatment of relapsed/refractory aggressive B-cell lymphoma

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Two autologous anti-CD19 chimeric antigen receptor (CAR) T cells (axicabtagene ciloleucel[axi-cel] and tisagenlecleucel[tisa-cel]) have been approved for marketing in Europe for the treatment of relapsed/refractory (R/R) Diffuse large B-cell lymphoma (DLBCL).


    Lymphoma

    The researchers retrospectively collected data on 70 patients who received commercial CAR T cells at their institution from January 2018 to November 2019.


     

    The results of multivariate analysis showed that the factors associated with poor PFS were the number of treatment lines (≥4) of CAR T cells (P = .


    immunity

    In summary, this analysis describes a study cohort of patients with R/R aggressive B-cell lymphoma using axi-cel and tisa-cel in the real world in Europe.


     

    Original source:

     

    Hideki Goto, Shinichi Makita, et al.


    Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed / refractory diffuse large B-cell lymphoma in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.